drugset
drugset / Trial / NCT02450032

Study to Determine the Antibody Response to 500µg G17DT in Treatment of Patients With Gastric Cancer

NCT02450032 ↗

Phase 2 Completed 12 enrolled Cancer Advances Inc.
NaSingle-groupOpen-labelTreatment

Summary

This study was designed to investigate the antibody response generated by a 500µg dose of G17DT in patients with gastric cancer.

Timeline

Start
2000-02
Primary completion
2001-05
Completion
2001-05

Drugs

EvaluationDrugModalityDoseRoute
Subject G17DT Immunogen Vaccine 500 ug Intramuscular

Indications

gastric cancer